Inventiva S.A. ADR (IVA): Price and Financial Metrics

Inventiva S.A. ADR (IVA): $4.34

0.12 (-2.69%)

POWR Rating

Component Grades








IVA Price/Volume Stats

Current price $4.34 52-week high $6.82
Prev. close $4.46 52-week low $2.22
Day low $4.33 Volume 2,045
Day high $4.51 Avg. volume 51,024
50-day MA $3.98 Dividend yield N/A
200-day MA $3.83 Market Cap 224.61M

IVA Stock Price Chart Interactive Chart >


  • Value is the dimension where IVA ranks best; there it ranks ahead of 64.97% of US stocks.
  • IVA's strongest trending metric is Quality; it's been moving down over the last 55 days.
  • IVA's current lowest rank is in the Momentum metric (where it is better than 21.69% of US stocks).

IVA Stock Summary

  • IVA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.62 -- higher than merely 6.75% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 306.63%, INVENTIVA SA's debt growth rate surpasses 96.01% of about US stocks.
  • Revenue growth over the past 12 months for INVENTIVA SA comes in at 208.04%, a number that bests 97.11% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IVA, based on their financial statements, market capitalization, and price volatility, are OMGA, PIRS, SYBX, PNT, and CDTX.
  • IVA's SEC filings can be seen here. And to visit INVENTIVA SA's official web site, go to

Inventiva S.A. ADR (IVA) Company Bio

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

IVA Latest News Stream

Event/Time News Detail
Loading, please wait...

IVA Latest Social Stream

Loading social stream, please wait...

View Full IVA Social Stream

Latest IVA News From Around the Web

Below are the latest news stories about INVENTIVA SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.

Inventiva reports 2023 Third Quarter Financial Information¹

Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelyRevenues of €1.9 million for the first nine months of 2023, compared to €0.1 million for the same period in 2022Estimated cash runway expected to be extended to beginning of Q3 2024 subject to meeting the conditions precedent to the disbursement of the secon

Yahoo | November 21, 2023

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected for presentation. The two abstracts show: the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and

Yahoo | November 6, 2023

Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls

Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls

Yahoo | October 27, 2023

Inventiva reports its 2023 first-half financial results and provides a corporate update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelRevenues amounted to €1.9 million for the first half of 2023In August 2023, Inventiva received a financing of approximately €35.7 million from new and existing investors consisting of €30.6 million from a capital increase and €5.1 million issuance of royalty cert

Yahoo | September 28, 2023

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and commercial milestone payments in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea.Pending regulatory approvals, Hepalys Pharma, Inc.

Yahoo | September 20, 2023

Read More 'IVA' Stories Here

IVA Price Returns

1-mo 11.28%
3-mo 20.22%
6-mo 15.43%
1-year -2.47%
3-year -64.94%
5-year N/A
YTD -2.69%
2022 -67.35%
2021 -5.79%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!